Skip to main navigation Skip to search Skip to main content

Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

  • Albert Oriol*
  • , Roman Hájek
  • , Ivan Spicka
  • , Irwindeep Sandhu
  • , Yael C. Cohen
  • , Moshe E. Gatt
  • , José Mariz
  • , Michele Cavo
  • , Jesús Berdeja
  • , Kexin Jin
  • , Merav Bar
  • , Prianka Das
  • , Ross La Motte-Mohs
  • , Yu Wang
  • , Deepak Perumal
  • , Luciano J. Costa
    • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology